UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
----------------
SCHEDULE 13D
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(AMENDMENT NO. 1)*
BIOCRAFT LABORATORIES, INC.
- --------------------------------------------------------------------
(Name of Issuer)
COMMON STOCK, PAR VALUE $0.01 PER SHARE
- --------------------------------------------------------------------
(Title of Class of Securities)
090587106
- --------------------------------------------------------------------
(CUSIP Number)
BRIAN S. SNYDER
BIOCRAFT LABORATORIES, INC.
18-01 RIVER ROAD
FAIR LAWN, NEW JERSEY 07410
(201) 703-0400
- --------------------------------------------------------------------
(Name, Address and Telephone Number of Person Authorized to Receive Notices and
Communications)
MAY 31, 1996
- --------------------------------------------------------------------
(Date of Event which Requires Filing of this Statement)
If the filing person has previously filed a statement on Schedule 13G to
report the acquisition which is the subject of this Schedule 13D, and is
filing this schedule because of Rule 13d-1(b)(3) or (4), check the following
box [ ]
Check the following box if a fee is being paid with this statement [ ]. (A fee
is not required only if the filing person: (1) has a previous statement on
file reporting beneficial ownership of more than five percent of the class of
securities described in Item 1; and (2) has filed no amendment subsequent
thereto reporting beneficial ownership of five percent or less of such class.)
(See Rule 13d-7.)
* The remainder of this cover page shall be filled out for a reporting
person's initial filing on this form with respect to the subject class of
securities, and for any subsequent amendment containing information which
would alter the disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be
deemed to be "filed" for the purpose of Section 18 of the Securities Exchange
Act of 1934 ("Act") or otherwise subject to the liabilities of that section of
the Act but shall be subject to all other provisions of the Act (however, see
the Notes).
<PAGE>
<TABLE>
SCHEDULE 13D
CUSIP NO. 090587106 PAGE 2 OF 5 PAGES
<S> <C> <C>
1. NAME OF REPORTING PERSONS
S.S. OR I.R.S IDENTIFICATION NO. OF ABOVE PERSONS
Brian S. Snyder
S.S. No. ###-##-####
- ------------------------------------------------------------------------------
2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) [ ]
(b) [ ]
- ------------------------------------------------------------------------------
3. SEC USE ONLY
- ------------------------------------------------------------------------------
4. SOURCE OF FUNDS* OO
- ------------------------------------------------------------------------------
5. CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS
REQUIRED PURSUANT TO ITEMS 2(D) OR 2(E) [ ]
- ------------------------------------------------------------------------------
6. CITIZENSHIP OR PLACE OF ORGANIZATION USA
- ------------------------------------------------------------------------------
NUMBER OF 7. SOLE VOTING POWER NONE
SHARES ------------------------------------------------------
BENEFICIALLY 8. SHARED VOTING POWER NONE
OWNED BY ------------------------------------------------------
EACH 9. SOLE DISPOSITIVE POWER NONE
REPORTING ------------------------------------------------------
PERSON WITH 10. SHARED DISPOSITIVE POWER NONE
- ------------------------------------------------------------------------------
11. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH
REPORTING PERSON NONE
- ------------------------------------------------------------------------------
12. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11)
EXCLUDES CERTAIN SHARES* [ ]
N/A
- ------------------------------------------------------------------------------
13. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) NONE
- ------------------------------------------------------------------------------
14. TYPE OF REPORTING PERSON* IN
- -------------------------------------------------------------------------------
</TABLE>
*SEE INSTRUCTIONS BEFORE FILLING OUT!
INCLUDE BOTH SIDES OF THE COVER PAGE, RESPONSES TO ITEMS 1-7
(INCLUDING EXHIBITS) OF THE SCHEDULE, AND THE SIGNATURE ATTESTATION.
Page 2 of [____] Pages
<PAGE>
ITEM 1. SECURITY AND ISSUER
This amends and supplements the statement on Schedule 13D
originally filed with the Securities and Exchange Commission on behalf
of Brian S. Snyder with respect to the common stock, par value $.01 per
share (the "Common Stock"), of Biocraft Laboratories, Inc., a Delaware
corporation (the "Company"). The address of the principal executive
offices of the Company is 18-01 River Road, Fair Lawn, New Jersey 07410.
The title of the class of equity securities to which this statement
relates is the Company's common stock, par value $.01 per share (the
"Common Stock").
Item 4 of the Schedule 13D is hereby amended by inserting the
following paragraph:
ITEM 4. PURPOSE OF TRANSACTION
On May 31, 1996, the consummation of the Agreement and Plan of
Merger dated as of January 29, 1996 (the "Merger Agreement) among Teva
Pharmaceutical Industries Limited, a corporation organized under the
laws of the State of Israel ("Teva"), Genco Merger Corporation, a
Delaware corporation and a wholly-owned subsidiary of Teva ("Merger
Sub"), and the Company occurred pursuant to which Merger Sub was merged
with and into the Company, with the Company continuing as the surviving
corporation (the "Merger"). As a result of the Merger, Teva owns 100% of
the outstanding voting securities of the Company and each outstanding
share of Common Stock of the Company was converted into the right to
receive 0.461 American Depositary Shares ("ADSs") of Teva, each ADS
representing 10 Ordinary Shares, par value NIS 0.01 each, of Teva.
Item 5 of the Schedule 13D is hereby amended in its entirety by
inserting the following paragraphs:
ITEM 5. INTEREST IN SECURITIES OF THE ISSUER
(a) None. As a result of the Merger, and assuming each share of Common
Stock of the Company held by the Reporting Person is converted into
the appropriate number of ADSs, the Reporting Person shall not
beneficially own any shares of the Company's Common Stock.
(b) None.
(c) None.
(d) None.
(e) May 31, 1996.
ITEM 6. CONTRACTS, ARRANGEMENTS, UNDERSTANDINGS OR RELATIONSHIPS WITH RESPECT TO
SECURITIES OF THE ISSUER.
See Item 4.
Page 3 of [____] Pages
<PAGE>
ITEM 7. MATERIAL TO BE FILED AS EXHIBITS
(a) Agreement and Plan of Merger dated as of January 29, 1996 among
Teva Pharmaceutical Industries Limited, Genco Merger Corporation
and Biocraft Laboratories, Inc. (incorporated by reference to the
Exhibit 2.1 of Teva's Registration Statement on Form F-4 filed by
Teva with the Securities and Exchange
Commission on April 29, 1996).
Page 4 of [____] Pages
<PAGE>
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true,
complete and correct.
Date: June 10, 1996
Signature: /s/ Brian S. Snyder
--------------------
Brian S. Snyder
Page 5 of [____] Pages
